Skip to content
EmergingResearch compoundLimited evidence

IDRA‑21

Experimental memory-boosting compound: improved learning in rodents and monkeys, never studied in humans.

NootropicAmpakineAmpakineMemoryGlutamateAMPANMDA
Available at

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

Pharmacology

ClassAmpakine · Memory
Primary targetAMPA receptor positive allosteric modulation
Targets3 receptor targets
Half-lifeNo human pharmacokinetic data (in primate studies cognitive effects lasted up to 48 hours)
OnsetNo human data
EvidenceLimited evidence
Affected systemsGlutamateAMPANMDA

Contents

DETAILED OVERVIEW

What is IDRA-21?

IDRA-21 is an experimental compound that has been studied in animals for improving learning and memory. It has not been approved as a medicine anywhere and was never cleared for human use; it exists only as an unregulated research chemical, not intended for human consumption.

It strengthens the signal of glutamate, one of the brain's main stimulating messengers: it slows the process by which the receiving receptor quickly stops responding, so communication between nerve cells can become stronger and longer-lasting. In rodents and monkeys it improved learning and memory, and the effect in monkeys lasted a long time. It has not been studied in humans, so there is practically no data on its safety or long-term effects. In theory it could cause anxiety, restlessness, sleep problems and headache, persistent overstimulation might damage nerve cells, and in people with epilepsy it could raise the risk of seizures. Safety in pregnancy and breastfeeding has not been established.

Mechanism

AMPA-PAM (slows desensitization)

Evidence

Preclinical only (no human data)

Legal status

Unapproved research chemical

Receptor profile

  • AMPA receptorsStrong
  • Long-term potentiation (LTP)Strong
  • NMDA receptors (indirect, AMPA-coupled)Moderate

Safety

Side effects, stop signs, contraindications

Side effects · 6

  • No human safety data: only preclinical (rodent and primate) studies exist; the compound has never been tested in humans
  • Possible glutamatergic overstimulation (anxiety, restlessness, insomnia) inherent to AMPA-positive modulation
  • Theoretical excitotoxicity risk at high doses from the sustained AMPA current
  • Possible headache typical of the ampakine and racetam class
  • Unknown long-term safety and incomplete toxicity profile in humans
  • Bell-shaped (inverted-U) dose-response observed in animals: more is not better and may abolish the effect

Contraindications · 4

  • Pregnancy and breastfeeding: safety not established, avoid
  • Epilepsy or lowered seizure threshold: AMPA potentiation may theoretically increase seizure risk
  • Avoid combining with other glutamatergic/stimulant agents due to excitotoxicity risk
  • Not an approved medicine; experimental research chemical, not recommended without clinical supervision

Related Nootropics

Same therapeutic category

Studies

Related research and clinical findings

FAQ

FAQ

IDRA-21 is an experimental research compound that has been studied in animals for its effects on learning and memory. The idea behind it is that it prolongs the action of one of the brain's main excitatory signaling chemicals, making communication between neurons stronger and longer-lasting. It's important to note there's essentially no human experience with it, everything known so far comes from rodent and primate studies.

Telegram

Have a question about IDRA‑21?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic
FormulaC8H9ClN2O2S
UpdatedOctober 14, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.